HeartStitch® has made significant steps toward full commercialization of the HeartStitch TA™, HeartStitch MR™, and HeartStitch AF™ devices. Below you will find links to our most recent press releases:
The HeartStitch TA™ has gained further recognition in recent news and was mentioned in “Femoral and Apical Closure Devices for TAVR”, by Jonathan White, MD, and Matthew Williams, MD, in the September/October 2014 issue of Cardiac Interventions Today.
For several years, HearStitch® has been at the forefront of suture-based closure applied in new and innovative ways to improve procedures, costs, recovery, and the quality of life for patients. As HeartStitch®’s devices have evolved, the Company and its technologies have been recognized alongside various methods and technologies explored in articles and publications by doctors and individuals in the medical and engineering fields.
In 2008, HeartStitch® received mention in “Patent Foramen Ovale: Current State of the Art,” by Ignacio Cruz-Gonzalez, Jorge Solis, Ignacio Inglessis-Azuaje, and Igor F. Palacios of the Cardiology Division at Massachussetts General Hospital in Boston, Massachussetts. In the same year, the Company was also mentioned in the Korean Circulation Journal‘s (Korean Society of Cardiology) “Patent Foramen Ovale and Cryptogenic Stroke,” by Kook-Jin Chun, MD.
HeartStitch’s current products include the HeartStitch TA™, HeartStitch MR™, and HeartStitch AP™. The HeartStitch TA™ and HeartStitch MR™ have received US FDA clearance for use in performing vascular stitching in general surgery, including endoscopic procedures. The HeartStitch MR™ & HeartStitch TA™ are not intended for blind vascular closure. The HeartStitch TA™ and HeartStitch MR™ are CE marked for cardiovascular suturing in the European Union. The HeartStitch AP™ is an investigational device and not for use in the United States or the European Union.